This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wolinsky, J. S Articles by PROMiSe Trial Study Group Search for Related Content PubMed PubMed Citation Articles by Wolinsky, J. S Articles by PROMiSe Trial Study Group, Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

The PROMiSe trial: baseline data review and progress report

University of Texas Health Science Center at Houston, Houston, TX, USA

PROMiSe Trial Study Group

The PROMiSe trial is a multinational, multicentre, double-blind, placebo-controlled trial evaluating the effects of glatiramer acetate treatment over 3 years in patients with primary progressive multiple sclerosis (PPMS). A total of 943 patients were enrolled, and all those remaining on-study had completed at least 24 months as of October 2002. Baseline clinical and MRI characteristics and select correlations are reported here. A total of 3.9% of patients exhibited confirmed relapse over 1904 patient-years of exposure, indicating success of efforts to exclude relapsing MS types. Of the 26.3% of patients who have prematurely withdrawn from the study, only 36% discontinued after meeting the study primary endpoint of disease progression. The progression rate in patients in the low Expanded Disability Status Scale (EDSS) stratum (3.0-5.0) observed thus far is markedly lower than the 50% annual progression rate estimate used for determining size and statistical power of the trial; progression was observed in 16.1% of patients with 12 months of study exposure. These early findings raise some concern about the ability of the trial to demonstrate a significant treatment effect, and suggest that the short-term natural history of PPMS may not be as aggressive as previously assumed.

Key Words: Key words: Primary progressive multiple sclerosis • magnetic resonance imaging • clinical trials • cerebrospinal fluid • diagnostic criteria

Multiple Sclerosis, Vol. 10, No. 1 suppl, S65-S72 (2004)
DOI: 10.1177/135245850401000112


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?